ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
128.957,09
2,64%
S&P 500
5.638,94
2,13%
US Dollar vs BRL
5,7456
0,02%
Bitcoin
84.239,99
0,33%
Brent Oil
70,285
0,00%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Candel Therapeutics Inc (CADL)

  7. Candel Therapeutics Inc (CADL) Notícias

CADL

Candel Therapeutics (CADL)

Candel Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CADL
DataHoraFonteTítuloCódigoCompanhia
13/03/202517:45Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CADLCandel Therapeutics Inc
13/03/202517:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CADLCandel Therapeutics Inc
13/03/202517:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
13/03/202517:15GlobeNewswire Inc.Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
25/02/202510:00GlobeNewswire Inc.Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
14/02/202519:32Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CADLCandel Therapeutics Inc
14/02/202518:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
15/01/202510:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CADLCandel Therapeutics Inc
13/01/202510:00GlobeNewswire Inc.Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025NASDAQ:CADLCandel Therapeutics Inc
16/12/202418:01GlobeNewswire Inc.Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNASDAQ:CADLCandel Therapeutics Inc
13/12/202418:36Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CADLCandel Therapeutics Inc
13/12/202401:00GlobeNewswire Inc.Candel Therapeutics Announces Pricing of Public OfferingNASDAQ:CADLCandel Therapeutics Inc
12/12/202418:51GlobeNewswire Inc.Candel Therapeutics Announces $80 Million Proposed Public OfferingNASDAQ:CADLCandel Therapeutics Inc
11/12/202409:00GlobeNewswire Inc.Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free SurvivalNASDAQ:CADLCandel Therapeutics Inc
14/11/202410:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CADLCandel Therapeutics Inc
14/11/202410:00GlobeNewswire Inc.Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
07/11/202410:00GlobeNewswire Inc.Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024NASDAQ:CADLCandel Therapeutics Inc
05/11/202411:00GlobeNewswire Inc.Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
28/10/202409:00GlobeNewswire Inc.Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)NASDAQ:CADLCandel Therapeutics Inc
04/10/202410:00GlobeNewswire Inc.Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
03/09/202409:00GlobeNewswire Inc.Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:CADLCandel Therapeutics Inc
13/08/202409:00GlobeNewswire Inc.Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
18/06/202409:00GlobeNewswire Inc.Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceNASDAQ:CADLCandel Therapeutics Inc
11/06/202409:00GlobeNewswire Inc.Candel Therapeutics to Join Russell 3000® IndexNASDAQ:CADLCandel Therapeutics Inc
30/05/202418:20Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CADLCandel Therapeutics Inc
30/05/202417:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CADLCandel Therapeutics Inc
30/05/202409:00GlobeNewswire Inc.FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
23/05/202418:00GlobeNewswire Inc.Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
22/05/202409:00GlobeNewswire Inc.Candel Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:CADLCandel Therapeutics Inc
20/05/202409:00GlobeNewswire Inc.Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CADL

Seu Histórico Recente

TG
N9B
Bandai Namco
XE
NFC
Netflix
TG
I5M
Iron Mountain
TG
ISHA
Intershop Communications
TG
PODB
Poland
XE
SLYG
Shelly
TG
0EEB
Republic of Romania
TG
FESE
Fidelity ESG USD EM Bond...
TG
CBRS
First Trust Global Funds
TG
ISAA
Israel Saat
ASX
EPX
EP&T Global
XE
FYEI
Fidelity EUR HY Corp Bon...
TG
FHTG
MFS Meridian Funds
TG
SJ3
Sherwin Williams
TG
AMEI
Amundi Luxembourg
TG
34LA
Alpine Immune Sciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios